Key points are not available for this paper at this time.
Circulating levels of IGF-I and IGFBP-3 may predict the risk of developing advanced-stage prostate cancer, but their utility for screening patients with incident prostate cancer may be limited.
June M. Chan (Wed,) studied this question.